Priscilla Chan on Broadening Rare-Disease Research

A short argument for putting research tools in more hands, with context on spinal muscular atrophy.

PCPriscilla ChanSpeaker
Channel
No Priors: AI, Machine Learning, Tech, & Startups
Published
Jul 7, 2026
Video
1:03
Read
1 min
Original
English
Open on YouTube
Scroll to read and the video shrinks to the bottom-right corner. Captions follow your reading language.
Reading languageAvailable in 2 languages
You're reading the original English.
SUMMARY

In 30 seconds

Priscilla Chan argues that rare diseases may be overlooked by research strategies focused on large populations. She suggests broader access to tools could support more targeted research; SMA already has active research and approved treatments.

  1. 1A long tailCommon disease categories contain many distinct subtypes, alongside rare diseases.
  2. 2Broader accessChan argues for giving more researchers tools to pursue neglected questions.
  3. 3SMA contextSMA has active research and approved treatments.

Takeaways

  1. Disease categories include many subtypes.
  2. Rare diseases can receive less attention in population-focused research.
  3. Chan favors broader access to research tools.
  4. SMA already has approved treatments.
FULL TEXT

Read the edited text by chapter

Transcript only
01

Researching the long tail

Priscilla Chan argues that disease categories contain many subtypes, and that rare conditions may receive less attention when research focuses on interventions affecting the largest numbers of people.

Priscilla Chan argues that disease categories contain many subtypes, and that rare conditions may receive less attention when research focuses on interventions affecting the largest numbers of people.

She proposes putting research tools in more people’s hands so that individuals and smaller groups can pursue conditions they care about. As an example, she mentions spinal muscular atrophy (SMA).

Chan suggests that studying a rare disease can also reveal broader biological mechanisms. This is an argument for widening research participation, not a guarantee that a particular tool or project will produce a treatment.

SMA is already the subject of active research and has approved treatments; it should not be understood from the clip’s headline as a disease nobody studies. For example, the FDA has approved gene therapy for specified SMA patients. [FDA announcement](https://www.fda.gov/news-events/press-announcements/fda-approves-gene-therapy-treatment-spinal-muscular-atrophy).

More from this channel

38:06EN
No Priors: AI, Machine Learning, Tech, & Startups· Oct 29, 2026Podcast · 3 speakersServal’s Jake Stauch on coding agents for enterprise ITGuest Jake Stauch · Host Sarah Guo, Elad GilStauch explains why Serval is challenging ServiceNow, how it approaches permissions and approvals, and why background agents remain difficult to deploy safely.Enterprise AICoding agentsWorkflow automation+2
39:23EN
No Priors: AI, Machine Learning, Tech, & Startups· Oct 15, 2026Podcast · 2 speakersThe Defenders' Window: Greg Brockman on AI-Generated Knowledge, Drug Discovery, and the New Physics of CybersecurityHost Sarah Guo, Elad GilOpenAI's president explains why solving open math problems is a proof point for science, how proactive agents change product form, and why security spending must exceed software spending.Security & safetyAI securitySafety & governance+3
1:09:44EN
No Priors: AI, Machine Learning, Tech, & Startups· Oct 9, 2026Podcast · 2 speakers10,000 GB300s for Four Weeks: Reflection’s Open-Model LedgerHost Sarah Guo, Elad GilMisha Laskin tells No Priors how Reflection trained Beam, why reinforcement learning outspent pre-training, and why the West needs its own open weights.Open source & communityOpen-weight modelsReinforcement Learning+3
35:39EN
No Priors: AI, Machine Learning, Tech, & Startups· Oct 2, 2026Podcast · 2 speakersCompute Scaled a Millionfold. Bandwidth Only 40x. Fractile Wants to Fix That RatioHost Sarah Guo, Elad GilIn the summer of 2022, Walter Goodwin founded Fractile in London to build very fast inference chips for the world's largest models.Infrastructure & deploymentInferenceAI cost & performance+3
42:44EN
No Priors: AI, Machine Learning, Tech, & Startups· Sep 24, 2026Podcast · 2 speakersThey Paid $7.7 Billion for a Broker — and Intend to Do One Deal a YearHost Sarah Guo, Elad GilSequence Holdings co-founder Michael Lee tells No Priors why owning a market leader, not selling it software, is how AI actually remakes an incumbent.Enterprise & strategyEnterprise AIAI Strategy+3
38:14EN
No Priors: AI, Machine Learning, Tech, & Startups· Sep 18, 2026Podcast · 2 speakersDiffusion Will Win Inference: Stefano Ermon Bets Parallel Tokens Beat Custom SiliconHost Sarah Guo, Elad GilThe Stanford diffusion pioneer tells No Priors why a 50-person lab is training language models that generate many tokens at once — and why that maps to GPUs the way transformers once mapped to training.Models & trainingInferenceAI cost & performance+3